Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5819597 | 0.97 | FFAR3 (0.50) | FFAR3LCKFYNALDH1A1KDM4E | |
| Acetic Acid SCHEMBL5870799 | 0.97 | — | — | |
| Acetic Acid SCHEMBL6335654 | 0.88 | FFAR3 (0.41) | FFAR3LCKFYNALDH1A1KDM4E | |
| Hexane SCHEMBL2705931 | 0.85 | AKR1B1 (0.48) | ALDH1A1TDP1HSD17B10KMT2A | |
| Acetic Acid SCHEMBL5358874 | 0.83 | FFAR3 (0.37) | FFAR3LCKFYNALDH1A1KDM4E | |
| Acetic Acid SCHEMBL6509092 | 0.83 | FFAR3 (0.37) | FFAR3LCKFYNALDH1A1KDM4E | |
| Oxalic Acid SCHEMBL17224590 | 0.83 | ALOX15 (0.42) | FFAR3ALDH1A1KDM4ETDP1CA2 | |
| Oxalic Acid SCHEMBL17224587 | 0.83 | ALOX15 (0.42) | FFAR3ALDH1A1KDM4ETDP1CA2 | |
| Diethylamine SCHEMBL6495398 | 0.80 | TP53 (0.53) | FFAR3LCKFYNALDH1A1KDM4E | |
| Methacrylic Acid SCHEMBL331477 | 0.79 | ALDH1A1 (0.38) | FFAR3LCKFYNALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109540869-A | A kind of SERS detection method of chlortetracycline hydrochloride | 集美大学 | 2019-03-29 | — | — | CN | disclosed |
| CN-102153539-B | As the 3-amino-pyrrolidine derivatives of chemokine receptor modulators | Because of C1-esteraseremmer-N parent corporation (US) | 2016-01-13 | — | — | CN | disclosed |
| US-20130177994-A1 | METHODS FOR QUANTITATIVE CHIRAL DETERMINATION OF THE d- AND l- ENANTIOMERS OF AMPHETAMINE AND METHAMPHETAMINE | CLINICAL REFERENCE LABORATORY, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2008065500-A2 | HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| CN-1293053-C | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders | HOFFMANN LA ROCHE (CH) | 2007-01-03 | — | — | CN | disclosed |
| US-7145009-B2 | Pirazino(aza)indole derivatives | VERNALIS RESEARCH LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20060160816-A1 | Pirazino(AZA) indole derivatives | VERNALIS RESEARCH LIMITED | 2006-07-20 | — | — | US | disclosed |
| CN-1741994-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP (US) | 2006-03-01 | — | — | CN | disclosed |
| CN-1659141-A | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders | HOFFMANN LA ROCHE (CH) | 2005-08-24 | — | — | CN | disclosed |
| EP-0977755-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2005-07-13 | — | — | EP | disclosed |
| WO-1997009046-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5554613-A | QUINUCLIDINE DERIVATIVES, QUALENE SYNTHASE INHIBITORS, TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS AND FUNGUS INFECTIONS | ZENECA LIMITED (GB) | 1996-09-10 | — | — | US | disclosed |
| EP-0603314-A4 | CHEMICAL COMPOUNDS. | SMITHKLINE BEECHAM CORP (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0603314-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0598093-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHETASE INHIBITORS | ZENECA LIMITED (GB) | 1994-05-25 | — | — | EP | disclosed |
| WO-1993024486-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHETASE INHIBITORS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993004686-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-18 | — | — | WO | disclosed |
| EP-0104727-B1 | PYRIDINYL-SUBSTITUTED BENZIMIDAZOLES AND QUINOXALINES | THE UPJOHN COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0104727-A1 | Pyridinyl-substituted benzimidazoles and quinoxalines | THE UPJOHN COMPANY (US) | 1984-04-04 | — | — | EP | disclosed |
| US-4430502-A | Pyridinyl substituted benzimidazoles and quinoxalines | THE UPJOHN COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160816-A1 | Pirazino(AZA) indole derivatives | PIR, GPR119, INMT | FFAR3 1217/4885LCK 4560/4885FYN 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.